Credit Suisse’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-223,993
| Closed | -$8.81M | – | 3213 |
|
|
2023
Q2 | $8.81M | Buy |
223,993
+106,193
| +90% | +$3.75M | 0.01% | 983 |
|
|
2023
Q1 | $2.87M | Buy |
117,800
+12,237
| +12% | +$268K | ﹤0.01% | 1656 |
|
|
2022
Q4 | $2.26M | Buy |
105,563
+24,098
| +30% | +$514K | ﹤0.01% | 1803 |
|
|
2022
Q3 | $1.46M | Buy |
81,465
+8,110
| +11% | +$106K | ﹤0.01% | 2056 |
|
|
2022
Q2 | $706K | Buy |
73,355
+12,514
| +21% | +$157K | ﹤0.01% | 2621 |
|
|
2022
Q1 | $1.02M | Buy |
60,841
+5,398
| +10% | +$79.8K | ﹤0.01% | 2531 |
|
|
2021
Q4 | $927K | Buy |
55,443
+13,414
| +32% | +$220K | ﹤0.01% | 3380 |
|
|
2021
Q3 | $683K | Buy |
42,029
+12,778
| +44% | +$139K | ﹤0.01% | 3606 |
|
|
2021
Q2 | $184K | Sell |
29,251
-31,904
| -52% | -$206K | ﹤0.01% | 4296 |
|
|
2021
Q1 | $379K | Sell |
61,155
-62,419
| -51% | -$379K | ﹤0.01% | 3913 |
|
|
2020
Q4 | $854K | Buy |
+123,574
| New | +$791K | ﹤0.01% | 3439 |
|
|
2020
Q2 | – | Sell |
-32,363
| Closed | -$111K | – | 4196 |
|
|
2020
Q1 | $111K | Sell |
32,363
-60,122
| -65% | -$351K | ﹤0.01% | 3797 |
|
|
2019
Q4 | $794K | Buy |
+92,485
| New | +$330K | ﹤0.01% | 3281 |
|
|
2017
Q2 | – | Sell |
-21,543
| Closed | -$79K | – | 3998 |
|
|
2017
Q1 | $79K | Sell |
21,543
-76,048
| -78% | -$321K | ﹤0.01% | 3710 |
|
|
2016
Q4 | $472K | Buy |
97,591
+64,160
| +192% | +$1.9M | ﹤0.01% | 3481 |
|
|
2016
Q3 | $1.54M | Buy |
33,431
+1,999
| +6% | +$113K | ﹤0.01% | 2579 |
|
|
2016
Q2 | $1.6M | Sell |
31,432
-9,645
| -23% | -$479K | ﹤0.01% | 2517 |
|
|
2016
Q1 | $1.74M | Buy |
41,077
+26,999
| +192% | +$1.38M | ﹤0.01% | 2309 |
|
|
2015
Q4 | $1.11M | Sell |
14,078
-3,245
| -19% | -$188K | ﹤0.01% | 2745 |
|
|
2015
Q3 | $702K | Sell |
17,323
-41,982
| -71% | -$2.22M | ﹤0.01% | 3136 |
|
|
2015
Q2 | $3.09M | Buy |
59,305
+23,548
| +66% | +$1.17M | ﹤0.01% | 2183 |
|
|
2015
Q1 | $1.66M | Sell |
35,757
-2,972
| -8% | -$154K | ﹤0.01% | 2543 |
|
|
2014
Q4 | $1.74M | Buy |
38,729
+29,813
| +334% | +$1.25M | ﹤0.01% | 2655 |
|
|
2014
Q3 | $346K | Sell |
8,916
-19,582
| -69% | -$769K | ﹤0.01% | 3858 |
|
|
2014
Q2 | $1.21M | Buy |
28,498
+22,339
| +363% | +$820K | ﹤0.01% | 3121 |
|
|
2014
Q1 | $219K | Buy |
+6,159
| New | +$208K | ﹤0.01% | 4297 |
|
Credit Suisse's ISEE Position: Q3 2023 in Review
Credit Suisse sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 223,993 shares — an estimated $8.81M sold.
Credit Suisse first reported a position in ISEE in Q1 2014 and held it in 26 quarters. The position peaked at $8.81M in Q2 2023. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Credit Suisse reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Credit Suisse sold 223,993 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $8.81M.
- Credit Suisse first reported a position in IVERIC bio, Inc. Common Stock in Q1 2014 and held it in 26 quarters.
- Credit Suisse's IVERIC bio, Inc. Common Stock position peaked at $8.81M in Q2 2023.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.